SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HuMAB companies

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who started this subject6/26/2001 4:18:20 AM
From: nigel bates   of 1022
 
MARTINSRIED, MUNICH, Germany, June 26 /PRNewswire/ -- The Munich-based biotechnology company MorphoSys AG (Neuer Markt: MOR) announced today a lawsuit initiated by Cambridge Antibody Technology Ltd. (CAT), together with The Medical Research Council and The Scripps Research Institute, alleging infringement of their ``Winter II'' US patent (No. 6,248,516) has been dismissed by the United States District Court for the Southern District of California in San Diego. The lawsuit was filed by CAT on June 19, 2001 and was dismissed by the court on Friday, June 22, 2001, for lack of jurisdiction and improper venue. MorphoSys has now filed an action for Declaratory Judgement in the U.S. District Court for the District of Columbia in Washington, D.C.
In Europe, a related Winter II patent was granted in 1994 and MorphoSys successfully opposed it at the European Patent Office (EPO) in October 1999. In its decision in 1999, the EPO requested substantial changes in the language of the key claim in the patent, thereby significantly narrowing the scope of protection...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext